Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

Satoru Taguchi1, Sebastiano Buti2, Hiroshi Fukuhara1*, Masafumi Otsuka1, Melissa Bersanelli2, Teppei Morikawa3, Hideyo Miyazaki1, Tohru Nakagawa1, Tetsuya Fujimura1, Haruki Kume1, Yasuhiko Igawa1, Yukio Homma1

1 Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2 Medical Oncology Unit, University Hospital of Parma, Parma, Italy, 3 Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

* hfukuhara-ju@umin.ac.jp

Abstract

Background
The benefit of adjuvant immunotherapy after nephrectomy in renal cell carcinoma (RCC) is controversial. The present study aimed to examine the possible benefit of adjuvant immunotherapy in various clinical settings.

Methods
We retrospectively reviewed 436 patients with pT1-3N0-2M0 RCC who underwent radical or partial nephrectomy with curative intent at our institution between 1981 and 2009. Of them, 98 (22.5%) patients received adjuvant interferon-α (IFN-α) after surgery (adjuvant IFN-α group), while 338 (77.5%) did not (control group). The primary endpoint was cancer-specific survival (CSS). Univariate and multivariate analyses were conducted using log-rank tests and Cox proportional hazards models, respectively.

Results
Fifty-two (11.9%) patients died from RCC with a median follow-up period of 96 months. Preliminary univariate analyses comparing CSS among treatment groups in each TNM setting revealed that CSS in the control group was equal or superior to that in the adjuvant IFN-α group in earlier stages, while the opposite trend was observed in more advanced stages. We evaluated the TNM cutoffs and demonstrated maximized benefit of adjuvant IFN-α in patients with pT2b-3cN0 (P = 0.0240). In multivariate analysis, ≥pT3 and pN1-2 were independent predictors for poor CSS in all patients. In the subgroups with ≥pT2 disease (n = 123), pN1-2 and no adjuvant treatment were significant poor prognostic factors.

Conclusions
Adjuvant immunotherapy after nephrectomy may be beneficial in pT2b-3cN0 RCC. Careful consideration is, however, required for interpretation of this observational study because of its selection bias and adverse effects of IFN-α.
Introduction

About a third of patients with localized renal cell carcinoma (RCC) treated by surgical resection will experience recurrence [1]. However, there is currently no established adjuvant treatment for patients after complete tumor resection [2–5]. A randomized trial conducted in the early 1980s comparing adjuvant radiotherapy after nephrectomy with observation showed no benefit of radiotherapy, with significantly increased post-radiation complications [2,3,6,7]. Based on promising data regarding the management of metastatic RCC, several randomized trials subsequently compared adjuvant interferon-α (IFN-α), high-dose interleukin-2 (IL-2) or cytokine combinations with observation alone in patients with locally advanced, completely resected RCC. However, none of these trials showed any benefit of adjuvant treatment in terms of time to relapse or improved survival [2,4,8–13]. Several phase III randomized controlled trials are currently investigating adjuvant treatment with tyrosine kinase or mammalian target of rapamycin inhibitors after nephrectomy in high-risk RCC [2,5,14]. The first of these “new generation” studies, the ASSURE trial, randomized 1943 patients with RCC to sunitinib, sorafenib, or placebo following complete resection, reported that adjuvant treatment with sorafenib or sunitinib did not improve relapse-free or overall survival (OS) compared with placebo [14,15]. Effective adjuvant treatment after nephrectomy, together with criteria for selecting suitable candidates, is therefore to be explored.

A recent phase III randomized trial comparing adjuvant immunotherapy with low-dose IL-2 plus IFN-α with observation alone after nephrectomy reported that pT3a (compared with other pT stages) could be a positive predictive factor in patients treated with adjuvant immunotherapy, maintaining its prognostic role in those not receiving adjuvant treatment [13].

In this context, the present study aimed to elucidate the optimal setting to maximize the benefit of adjuvant immunotherapy after nephrectomy in a Japanese population with RCC.

Materials and methods

Patients and treatments

This retrospective study was approved by the institutional review board and was conducted in accordance with the Declaration of Helsinki. We retrospectively reviewed 528 patients with pathologically confirmed RCC who underwent radical or partial nephrectomy at The University of Tokyo Hospital between 1981 and 2009 (Fig 1). Distant metastasis at initial diagnosis (n = 49), prior nephrectomy at other institutions (n = 2), von Hippel-Lindau disease (n = 9) and insufficient clinical information (n = 32) were excluded from this analysis. A total of 436 patients with pT1-3N0-2M0 sporadic RCC who underwent either radical or partial nephrectomy with curative intent were finally reviewed, including 98 (22.5%) who received adjuvant IFN-α treatment after surgery (adjuvant IFN-α group) and 338 (77.5%) who did not (control group). Each treatment was assessed by physicians’ discretion. The adjuvant IFN-α regimens were as follows: Sumiferon® (Sumitomo Dainippon Pharma, Osaka, Japan) 3–6×10⁶ IU; OIF® (Otsuka Pharmaceutical, Tokyo, Japan) 5×10⁶ IU; or Intron® A (Merck Sharp & Dohme, Tokyo, Japan) 3–6×10⁶ IU, injected subcutaneously two to three times per week. Pathological stage was re-evaluated according to the 7th TNM classification of the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) Guidelines [16]. This TNM re-evaluation was conducted in a comprehensive manner, based on pathology reports, medical charts, radiogram interpretation reports, and so on. Histological subtype and tumor grade were assessed according to 3rd World Health Organization Classification of Tumours [17] and the Heidelberg classification [18], respectively. These are the main criteria currently used in Japan for the pathological diagnosis of RCC [19]. All patients
underwent preoperative and postoperative (every 1–6 months) evaluations, including routine blood tests, chest x-rays, and computed tomography. Bone scintigraphy was performed when indicated. Postoperative monitoring included routine chest x-rays every 3 months and/or chest and abdominal computed tomography every 6 months in the first 3 years, and yearly thereafter.

Statistical analyses
The primary endpoint was cancer-specific survival (CSS). Secondary endpoints were OS and recurrence-free survival (RFS). Survival curves were drawn using the Kaplan—Meier method. Univariate and multivariate analyses were performed using log-rank tests and Cox proportional hazards model, respectively. All statistical analyses were performed using JMP Pro version 11.0.0 (SAS Institute, Cary, NC, USA). A value of \( P < 0.05 \) was considered significant. Follow-up information was obtained up to December 2015.

Results
Patient characteristics
Fifty-two (11.9%) patients died from RCC with a median follow-up period of 96 months. The patient characteristics are summarized in Table 1. \( pT \) stage, \( pN \) stage, and grade were
significantly higher in the adjuvant IFN-α group, but there were no significant differences in age, sex, histological subtype, and follow-up period between the two groups. The surgical procedures were open radical nephrectomy in 253 (58.0%), open partial nephrectomy in 120 (27.5%), laparoscopic radical nephrectomy in 61 (14.0%), and laparoscopic partial nephrectomy in two (0.5%) patients; there was no difference of the surgery type among the two groups. The data on adjuvant IFN-α duration were available in 51 of 98 (52%) patients: their median IFN-α duration was 10 months (range: 1–175 months).

Treatment outcomes

We conducted preliminary univariate analyses to compare CSS between the adjuvant IFN-α and control groups in each TNM setting (Fig 2). CSS in the control group was equal or superior to that in the adjuvant IFN-α group in earlier stages (pT1aN0, pT1bN0, pT2aN0), but the opposite trend was observed in more advanced stages (pT2bN0, pT3aN0, pT3b-cN0, pT4aN1-2). Based on these findings, we evaluated the TNM cutoffs and demonstrated that adjuvant IFN-α had maximal benefit in patients with pT2b-3cN0 (P = 0.0240) (Fig 3). S1 Fig presents this result in another way: CSS in patients with pT2b-3cN0 was similar to that for pT1a-2aN0 in the adjuvant IFN-α group, but significantly worse in the control group. Similar trends were observed for the secondary endpoints (OS and RFS) (S2 Fig).

Table 1. Patient characteristics.

| Parameter                  | Total (n = 436) | Adjuvant IFN-α (n = 98) | Control (n = 338) | P     |
|----------------------------|-----------------|------------------------|-------------------|-------|
| Age at surgery, years, median (IQR) | 59 (50–67)      | 57 (48–66)             | 59 (51–68)        | 0.0631a |
| Gender, no. (%):            |                 |                        |                   | 0.3339b |
| Male                       | 331 (75.9)      | 78 (79.6)              | 253 (74.9)        |       |
| Female                     | 105 (24.1)      | 20 (20.4)              | 85 (25.1)         |       |
| pT stage, no. (%):         |                 |                        |                   | <0.0001*ab |
| T1a                        | 202 (47.9)      | 12 (12.2)              | 190 (56.2)        |       |
| T1b                        | 111 (25.5)      | 28 (28.6)              | 83 (24.6)         |       |
| T2a                        | 45 (10.3)       | 16 (16.3)              | 29 (8.6)          |       |
| T2b                        | 9 (2.1)         | 4 (4.1)                | 5 (1.5)           |       |
| T3a                        | 59 (13.5)       | 34 (34.7)              | 25 (7.4)          |       |
| T3b                        | 4 (0.9)         | 3 (3.1)                | 1 (0.3)           |       |
| T3c                        | 6 (1.4)         | 1 (1.0)                | 5 (1.5)           |       |
| pN stage, no. (%):         |                 |                        |                   | 0.0001*ab |
| N0/x                       | 422 (96.8)      | 89 (90.8)              | 333 (98.5)        |       |
| N1-2                       | 14 (3.2)        | 9 (9.2)                | 5 (1.5)           |       |
| Histological subtype, no. (%): |               |                        |                   | 0.9325b |
| Clear cell                 | 395 (90.6)      | 89 (90.8)              | 306 (90.5)        |       |
| Non-clear cell             | 41 (9.4)        | 9 (9.2)                | 32 (9.5)          |       |
| Grade                      |                 |                        |                   | 0.0212*ab |
| G1                         | 96 (22.0)       | 13 (13.3)              | 83 (24.6)         |       |
| G2                         | 295 (67.7)      | 70 (71.4)              | 225 (66.6)        |       |
| G3                         | 45 (10.3)       | 15 (15.3)              | 30 (8.9)          |       |
| Median follow-up, months (IQR) | 96 (45–140)    | 96 (43–163)            | 96 (46–135)       | 0.1235a |

IQR = interquartile range
* Statistically significant;
a Student’s t-test;
b Pearson’s χ² test
doi:10.1371/journal.pone.0172341.t001
Fig 2. Kaplan–Meier curves depicting CSS in adjuvant IFN-α and control groups in each TNM setting. CSS in the control group was equal or superior to that in the adjuvant IFN-α group in earlier stages (pT1aN0, pT1bN0, pT2aN0), but the opposite trend was observed in more advanced stages (pT2bN0, pT3aN0, pT3b-cN0, pTanyN1-2). doi:10.1371/journal.pone.0172341.g002
In addition to TNM, histological subtype (clear cell vs. non-clear cell) and grade (G1-2 vs. G3) were also associated with CSS in univariate analysis. However, multivariate analysis only identified \( pT3 \) and \( pN1-2 \) as independent predictors of poor CSS in the overall population (Table 2). For reference, multivariate analysis in the subgroup of patients with \( pT2 \) disease \((n = 123)\) detected \( pN1-2 \) and omission of adjuvant treatment as independent poor prognostic factors (Table 3).

**Discussion**

The present study demonstrated that the benefit of adjuvant IFN-\( \alpha \) after nephrectomy was detected in patients with \( pT2b-3cN0 \) RCC. CSS was significantly prolonged in this subgroup following adjuvant IFN-\( \alpha \) treatment, compared with the control group. Adjuvant immunotherapy improved the prognosis of patients with \( pT2b-3cN0 \) tumors to a similar risk level to those with lower pathological stages. The CSS curves for patients with lower or higher \( pT \) were not significantly affected by adjuvant therapy, apart from a slight tendency towards a detrimental effect for \( pT1a-2aN0 \). Similar trends were also observed for the other endpoints of OS and RFS. Furthermore, although adjuvant IFN-\( \alpha \) was not prognostic in the study population as a whole, it was a good independent prognostic factor in patients with \( \geq pT2 \) disease.
To the best of our knowledge, six previously published randomized trials have compared cytokine-based (IFN-α and/or IL-2) adjuvant treatment with observation after nephrectomy, all of which failed to show any survival benefit of adjuvant immunotherapy [8–13]. The results of previous retrospective studies assessing the efficacy of adjuvant immunotherapy were also

| Parameter         | Cutoff   | Univariate | Multivariate |
|-------------------|----------|------------|--------------|
|                   |          | P          | HR (95% CI)  | P             |
| Age at surgery    | <59 years† | 0.8166     | Reference    | 0.3700        |
|                   | ≥59 years† |           | 0.764 (0.417 to 1.375) |          |
| Gender            | Male     | 0.2279     | Reference    | 0.5962        |
|                   | Female   |           | 0.822 (0.369 to 1.646) |          |
| pT stage          | T2       | <0.0001*   | Reference    | <0.0001*      |
|                   | T3       |           | 4.338 (2.187 to 8.442) |          |
| pN stage          | N0/x     | <0.0001*   | Reference    | 0.0296*       |
|                   | N1-2     |           | 3.275 (1.132 to 8.625) |          |
| Histological subtype | Clear cell | 0.0324* | Reference | 0.7989 |
|                   | Non-clear cell | | 1.121 (0.439 to 2.553) | |
| Grade             | G1-2     | <0.0001*   | Reference    | 0.9073        |
|                   | G3       |           | 2.221 (0.982 to 4.605) |          |
| Treatment group   | Adjuvant IFN-α | 0.0005* | Reference | 0.0013* |
|                   | Control  |           | 1.040 (0.532 to 1.997) |          |

HR = hazard ratio; CI = confidence interval
† Median;
* statistically significant

doi:10.1371/journal.pone.0172341.t002

To the best of our knowledge, six previously published randomized trials have compared cytokine-based (IFN-α and/or IL-2) adjuvant treatment with observation after nephrectomy, all of which failed to show any survival benefit of adjuvant immunotherapy [8–13]. The results of previous retrospective studies assessing the efficacy of adjuvant immunotherapy were also

| Parameter         | Cutoff   | Univariate | Multivariate |
|-------------------|----------|------------|--------------|
|                   |          | P          | HR (95% CI)  | P             |
| Age at surgery    | <59 years† | 0.6429     | Reference    | 0.2517        |
|                   | ≥59 years† |           | 0.672 (0.332 to 1.323) |          |
| Gender            | Male     | 0.4567     | Reference    | 0.7167        |
|                   | Female   |           | 0.861 (0.355 to 1.871) |          |
| pT stage          | T2       | 0.0553     | Reference    | 0.1182        |
|                   | T3       |           | 1.746 (0.869 to 3.636) |          |
| pN stage          | N0/x     | <0.0001*   | Reference    | 0.0013*       |
|                   | N1-2     |           | 5.163 (1.973 to 12.48) |          |
| Histological subtype | Clear cell | 0.5811 | Reference | 0.9870 |
|                   | Non-clear cell | | 1.008 (0.369 to 2.430) | |
| Grade             | G1-2     | 0.0727     | Reference    | 0.3716        |
|                   | G3       |           | 1.492 (0.598 to 3.328) |          |
| Treatment group   | Adjuvant IFN-α | 0.2354 | Reference | 0.0210* |
|                   | Control  |           | 2.227 (1.128 to 4.532) |          |

HR = hazard ratio; CI = confidence interval
† Median;
* statistically significant

doi:10.1371/journal.pone.0172341.t003
generally disappointing [20–23]. However, unplanned subgroup analysis of a randomized trial by Passalacqua et al. reported that pT3a (compared with other pT stages) could be a positive predictive factor in patients treated with adjuvant therapy, maintaining its prognostic role in the control group [13]. The authors developed a scoring model comprising pN (N0 vs. N1-2), tumor grade (Fuhrman G1-2 vs. G3-4), pT stage (pT3a vs. others [pT1-2 & pT3b-3c] according to the 6th edition of the UICC-AJCC TNM staging system [24]), and age (<60 vs. ≥60 years), and observed better RFS and OS outcomes in the adjuvant-treatment arm in patients with higher scores (i.e., ≥2 vs. 0–1 factors among pN0, G1-2, pT3a, and age ≤60 years) [13]. The results of the current study were generally in accordance with this Passalacqua’s report, indicating maximal benefit of adjuvant immunotherapy in patients with pT2b-3c (around pT3a) but without nodal metastasis (pN0). It is necessary to point out that the TNM classification for pT3a has been modified over time, from being defined as the extension to “perinephric tissue, renal sinus, or contiguous into adrenal gland” (T3b for renal vein involvement) in 2002 [24], to include “perinephric tissue, renal sinus, or renal vein” (the adrenal gland involvement was attributed to T4) in 2010 [16]. In the present study, the pathological stage was revised according to the 7th TNM classification.

IFN-α has established roles in the treatment of RCC in the metastatic setting [2] and malignant melanoma in both adjuvant and metastatic settings [25], but its mechanism of action has not been fully elucidated. Researchers have speculated that IFN-α may exert its antitumor efficacy mainly by indirect immunomodulatory effects, involving several mechanisms. These include an increase in tumor-infiltrating cells, decrease in circulating regulatory T cells, manifestations of autoimmunity and development of autoantibodies, changes in cytokine concentrations, modulation of signal transducer and activator of transcription (STAT) 1/STAT3 balance in tumor cells and host lymphocytes, and normalization of T cell STAT1 signaling defects in peripheral blood lymphocytes [26]. These indirect immunomodulatory effects are assumed to be enhanced under certain levels of tumor burden. Our results suggested that tumor-associated antigens might be highly presented to the systemic circulation in patients with ≥pT2b disease, which could strengthen the antitumor actions of adjuvant IFN-α (e.g., preventing further growth of micrometastases). Conversely, these indirect effects are less powerful and might thus be unable to improve the anti-tumor response in more advanced settings (pN1-2), resulting in an optimal response in patients with moderately advanced tumors (pT2b-3cN0).

According to our analysis, adjuvant IFN-α was associated with poorer CSS compared with the control group in patients with earlier stage RCC, such as pT1bN0. It might be caused by the selection bias that patients with higher grade tumors were more assigned to adjuvant IFN-α treatment. However, the previous randomized trial also reported a similar trend of poorer outcomes associated with adjuvant treatment in earlier stages, suggesting that adjuvant immunotherapy may indeed have a detrimental effect in earlier stage RCC [13]. Another randomized trial conducted in Japan also reported a similar trend, with higher RFS in the observation group compared with the interferon group in T1 or T2 subjects, but higher RFS in the interferon group over 3 years in T3 subjects, though the difference was not significant [12]. No other study of the said six trials assessing cytokine-based adjuvant therapy after nephrectomy compared treatment outcomes in a TNM subgroup [8–11]. Nevertheless, its minimal or negative impact on survival, together with its well-known adverse effects such as fatigue, headache, muscle pain, and depression, means that adjuvant IFN-α should be cautiously indicated. Attention should also be paid to the fact that these adverse effects of IFN-α are quite different from those of tyrosine kinase inhibitors including hypertension, hand-foot syndrome, rash and fatigue [15].
This study had some limitations, including its retrospective design and potential selection bias. Given the mechanism of action of immunotherapy, the results of this study might be useful for trials of emerging immune checkpoint inhibitors [5,13].

Conclusions

The benefit of adjuvant immunotherapy was most significant in RCC patients with pT2b-3cN0. Careful consideration is, however, required for interpretation of this observational study because of its selection bias and adverse effects of IFN-α. Further studies are required to validate these results and aid the establishment of optimal patient-selection criteria for trials of adjuvant immunotherapy after nephrectomy.

Supporting information

S1 Dataset. The clinical and pathological data of all the subjects.

S1 Fig. Kaplan—Meier curves depicting CSS in pT1a-2aN0, pT2b-3cN0, and pTanyN1-2 patients among (A) all patients, (B) adjuvant IFN-α group, and (C) control group, respectively (all \( P<0.0001, \log_{-}\text{-rank test} \)). CSS in pT2b-3cN0 was similar to that in pT1a-2aN0 in the adjuvant IFN-α group, but significantly worse in the control group.

S2 Fig. Kaplan—Meier curves depicting OS in pT1a-2aN0, pT2b-3cN0, and pTanyN1-2 patients among (A) all patients, (B) adjuvant IFN-α group, and (C) control group, respectively (ditto with RFS). Similar trends to CSS were observed for both OS and RFS.

Acknowledgments

We received no funding/grant support for this study.

Author Contributions

Conceptualization: ST SB HF.

Data curation: ST HF.

Formal analysis: ST HF.

Investigation: ST HF MO.

Methodology: ST SB HF.

Project administration: ST SB HF.

Resources: TM.

Software: ST.

Supervision: YH.

Visualization: ST.

Writing – original draft: ST SB HF MB.

Writing – review & editing: HM TN TF HK YI YH.
References

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353: 2477–2490. doi: 10.1056/NEJMra043172 PMID: 16339096

2. Motzer RJ, Jonasch E, Agarwal N, Beard C, Bhayani S, Bolger GB, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Kidney Cancer Version 2.2014. Fort Washington: National Comprehensive Cancer Network, Inc.; 2014.

3. Yap TA, Eisen TG. Adjuvant therapy of renal cell carcinoma. Clin Genitourin Cancer 2006; 5: 120–130. doi: 10.3816/CGC.2006.n.028 PMID: 17026800

4. Smaldone MC, Fung C, Uzzo RG, Haas NB. Adjuvant and neoadjuvant therapies in high-risk renal cell carcinoma. Hematol Oncol Clin North Am 2011; 25: 765–791. doi: 10.1016/j.hoc.2011.06.002 PMID: 21763967

5. Buti S, Bersanelli M, Donini M, Ardizzoni A. Systemic adjuvant therapies in renal cell carcinoma. Oncol Rev 2011; 25: 765–791. doi: 10.1016/j.hoc.2011.06.002 PMID: 21763967

6. Kjaer M, Frederiksen PL, Engelholm SA. Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 1987; 13: 665–672. PMID: 3553111

7. Kjaer M, Iversen P, Hvidt V, Bruun E, Skaarup P, Bech Hansen J, et al. A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 1987; 21: 285–289. doi: 10.3109/0036559790190784 PMID: 3445125

8. Pizzocaro G, Piva L, Colavita M, Ferri S, Artusi R, Boracchi P, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001; 19: 425–431. PMID: 11208835

9. Messing EM, Manola J, Wilding G, Propert K, Fleischmann J, Crawford ED, et al; Eastern Cooperative Oncology Group/Intergroup trial. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 2003; 21: 1214–1222.

10. Clark JI, Atkins MB, Urba WJ, Creech S, Figlin RA, Dutcher JP, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003; 21: 3133–3140. PMID: 12810695

11. Atzpodien J, Schmitt E, Gertenbach U, Fornara P, Heynemann H, Maskow A, et al; German Cooperative Renal Carcinoma Chemo-Immunotherapy Trials Group (DGCIN). Adjuvant treatment with interleukin-2- and interferon-alpha2a-based chemoimmunotherapy in renal cell tumour post nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 2005; 92: 843–846. doi: 10.1038/sj.bjc.6602443 PMID: 15756254

12. Hinotsu S, Kawai K, Ozono S, Tsushima T, Tokuda N, Nomata K, et al. Randomized controlled study of natural interferon α as adjuvant treatment for stage II or III renal cell carcinoma. Int J Oncol 2013; 18: 68–74. doi: 10.1007/s10147-011-0345-9 PMID: 22068465

13. Passalacqua R, Caminiti C, Buti S, Porta C, Camisa R, Braglia L, et al; POLAR-01 Trial Investigators. Adjuvant low-dose interleukin-2 (IL-2) plus interferon-α (IFN-α) in operable renal cell carcinoma (RC): a phase III, randomized, multicentre trial of the Italian Oncology Group for Clinical Research (GOIRC). J Immunother 2014; 37: 440–447.

14. Bex A, Powles T, Karam JA. Role of targeted therapy in combination with surgery in renal cell carcinoma. Int J Urol 2016; 23: 5–12. doi: 10.1111/iju.12891 PMID: 26238981

15. Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 2016; 387: 388: 2008–2016. doi: 10.1016/S0140-6736(16)00559-6 PMID: 26969090

16. Edge SB, Byrd DR, Compton CC, Fritz A, Greene FL, Trotti A, et al, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.

17. Eble JN, Sauter G, Epstein JI, Sesterhenn I, editors. WHO/IARC Classification of Tumours, 3rd Edition, Volume 7: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004.

18. Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, et al. The Heidelberg classification of renal cell tumours. J Pathol 1997; 183: 131–133. doi: 10.1002/(SICI)1096-9896(199710183:2<131::AID-PATH931>3.0.CO;2-G PMID: 9390023
19. The Japanese Urological Association, The Japanese Society of Pathology, Japan Radiological Society: General Rule for Clinical and Pathological Studies on Renal Cell Carcinoma, The 4th Edition (in Japanese). Tokyo: Kanehara-shuppan Press; 2011.

20. Migliari R, Muscas G, Solinas A, Melis M, Ionta MT, Massidda B, et al. Is there a role for adjuvant immunochemotherapy after radical nephrectomy in pT2-3N0M0 renal cell carcinoma? J Chemother 1995; 7: 240–245. doi: 10.1179/joc.1995.7.3.240 PMID: 7562021

21. Basting R, Corvin S, Händel D, Hinke A, Schmidt D. Adjuvant immunotherapy in renal cell carcinoma—comparison of interferon alpha treatment with an untreated control. Anticancer Res 1999; 19: 1545–1548. PMID: 10365142

22. Hong SK, Kwak C, Lee SE. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma. Urology 2005; 66: 518–522. doi: 10.1016/j.urology.2005.04.014 PMID: 16140069

23. Levakov I, Vojnov S, Jeremić D, Dozić J, Vignjević O. Postoperative influence of interferon alpha on patients with renal cell carcinoma. Med Pregl 2011; 64: 173–177. PMID: 21905595

24. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, et al, editors. AJCC cancer staging manual. 6th ed. New York: Springer; 2002.

25. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE 3rd, et al. Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2016; 14: 450–473. PMID: 27059193

26. Di Trolio R, Simeone E, Di Lorenzo G, Buonerba C, Ascierto PA. The use of interferon in melanoma patients: a systematic review. Cytokine Growth Factor Rev 2015; 26: 203–212. doi: 10.1016/j.cytogfr.2014.11.008 PMID: 25511547